Using Epic® Capabilities

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

To Include BLENREP in Treatment Plans, Send Ophthalmic Exam Notifications, and Monitor Patients' Results

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Notable requirements of the BLENREP REMS include the following:

Prescribers must be certified in the BLENREP REMS by enrolling and completing training. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide. Patients must be enrolled in the BLENREP REMS and adhere to monitoring. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling and must obtain authorization prior to dispensing. Wholesalers and distributors must distribute BLENREP only to certified healthcare settings.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

About This Guide

This electronic health record (EHR) guide is intended to help healthcare providers (HCPs) use Epic® capabilities to facilitate accurate prescribing for BLENREP. It includes steps and examples for adding BLENREP to Treatment Plans, automating notifications for HCPs and patients about REMS requirements, the need for ophthalmic exams and complete blood count (CBC) tests as directed in the USPI, and customizing Flowsheets to capture and monitor patients' overall ophthalmic exam results grading which can be used to inform BLENREP treatment decisions in line with the USPI.

This guide does not constitute guidance for treatment or medical advice. It is the HCP's responsibility to select a treatment based on their independent medical judgment and the needs of each individual patient.

The examples and instructions listed in this guide are based on the most recent version of Epic. Locations, illustrations, and terminology are subject to change with system updates. This guide is meant to serve as an overview only and should not replace detailed instructions provided to you by your internal or external EHR support resources. GSK makes no claims or warranties about the applicability or appropriateness of this information. This guide has not been reviewed or endorsed by Epic. GSK does not endorse or recommend any EHR system.

Use the links in the table of contents below or the tabs on each page to navigate this guide.

Table of Contents

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a New Order Group to Include BLENREP

When new information or data become available, oncology practices may add or update Order Groups and Treatment Plans (using the Protocol Builder). Order Groups are components of Treatment Plans that include administration instructions as well as necessary tests such as ophthalmic exams and REMS requirements (i.e., completed and submitted Patient Status Form before each dose of BLENREP and obtaining authorization to dispense for all doses).

Prescribers must be certified in the BLENREP REMS by enrolling and completing training at www.BLENREPREMS.com. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling at www.BLENREPREMS.com and must obtain authorization prior to dispensing BLENREP. Once a new BLENREP Order Group is set up, it can be added to an appropriate Treatment Plan.

NOTE: *The specific Order Group components listed below are for illustrative purposes only.*

Steps for Creating an Order Group

1. Select the **Epic®** button > **Admin** > **Beacon™ Admin** > **Order Group Builder** to open the **Order Group Builder**.
2. Select the **Create** tab.
3. Enter the **Name** of the **Order Group** to be set up.
4. Select **Accept** on the initial contact date to open the **Order Group Builder**.
5. Populate appropriate **Order Group Properties**. Enter a **Selection mode** and **Default category**. Add **Synonyms** to help when searching for **Order Groups**.
6. Select **Add Order**.
7. Search for **Order** and select an appropriate **Category**.
8. Enter **BLENREP** in the **Order** field and select **Accept**.



Illustrative example of Order Group Builder (recreated from Epic)

Illustrative example of Add Order (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a New Order Group to Include BLENREP (cont.)

Steps for Creating an Order Group (cont.)

9. Enter all the **Medication Details** as appropriate, including dose, route, frequency, starting time, patient weight, and other additional order instructions such as ensuring the prescriber and healthcare setting are certified in the REMS, patient is enrolled in the REMS, authorization to dispense is obtained, instructions to nurses to follow up with Eye Care Professionals if the BLENREP REMS Eye Care Professional Exam Form is still pending before infusion appointment, and notes to Pharmacy that a Patient Status Form has been completed.
10. Select **Accept**.
11. Repeat process to add cycle-specific associated therapy orders, such as complete blood count (CBC), Pregnancy Test for appropriate patients, mandatory ophthalmic exam, Patient Status Form submitted to REMS before each dose of BLENREP to document prescriber confirmation that they assessed the patient's ophthalmic examination findings and authorized treatment, and patient education for BLENREP treatment including the BLENREP REMS Patient Guide.
    a. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide.



Illustrative example of Medication Details (recreated from Epic)

12. After all orders have been added, **Release** the Order Group to make the changes.

Include the BLENREP REMS Eye Care Professional Exam Form available at **www.BLENREPREMS.com** as part of the BLENREP SmartSet. The form should be completed by the patient's optometrist or ophthalmologist and sent (via eFax, Fax, EMR, or by the patient) to the oncologist at the close of the patient's eye exam to give the oncologist time to determine appropriate treatment dosing prior to administration of BLENREP. If supported, work with your EHR IT team to add the form as a custom resource.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 25% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding the BLENREP Order Group to a Treatment Plan Using the Protocol Builder

Treatment Plans help care teams facilitate care by grouping together clinical actions that will be administered to a patient during multiple encounters over a specific time frame. Once a new BLENREP Order Group has been set up, it can be added to an appropriate Treatment Plan.

Steps for Adding an Order Group

1. Click the **Epic®** button > **Admin** > **Beacon™ Admin** > **Protocol Builder** search window.
2. Select the appropriate record and select **Accept**.
3. In the Version window, create a **New** record and make the **Protocol** editable.
4. In the Protocol Builder, identify where the **Order Group** should be added. Identify the appropriate **Cycle** and **Days** within the **Cycle** to add the **Order Group**.
5. Open the **Cycle** by selecting ⌃⌃ before the cycle name and select the **Day**.
6. Open the **Day** and select the appropriate **Order Group** to add the new **Order Group**.
7. Select **Add Order Group**.
8. In **Select Order Group**, search for and select the **Order Group ID** or **Name** that was created.
9. Add the **Order Group** to all **Cycles** and **Days** as appropriate.
10. After all orders have been added, **Release** the **Order Group** to make the changes available.



Illustrative example of adding Cycles (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

The most commonly reported corneal exam findings included superficial punctate keratopathy, microcyst-like deposits, epithelial changes, and haze. Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.

A reduction in BCVA to 20/50 or worse in at least one eye occurred in 69% of patients, including 29% who experienced a change in BCVA to 20/100 or worse, and 12% who experienced a change in BCVA to 20/200 or worse. Of the patients with reduced BCVA to 20/50 or worse in at least one eye, 61% had resolution of the last event to baseline or better. Of the patients with reduced BCVA to 20/100 or worse, 57% had resolution of the last event. Of the patients with reduced BCVA to 20/200 or worse, 48% had resolution of the last event.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding the BLENREP Order Group to a Treatment Plan Using the Protocol Builder (cont.)

BLENREP Patient Reminders

This workflow allows HCPs to draft and set up Patient Reminders that are delivered to patients via MyChart. By adding Patient Reminders to a BLENREP Order Group, patients who are prescribed BLENREP will automatically receive a patient portal message with a reminder to complete requirements prior to administration of BLENREP, including patient enrollment in the BLENREP REMS to document that they were counseled and agree to adhere to ophthalmic monitoring, required ophthalmic exams, etc.

NOTE: *A prerequisite for this workflow is that the practice uses a unique Visit Type for BLENREP appointments. The trigger for the patient reminder is the BLENREP visit type.*

STEP 1: CREATING A NEW SMARTTEXT

1. **Chart Search** > **Appointment Letter**.
2. Create **New**.
3. **Name:** "MyChart BLENREP Appointment Reminder."
4. Click **Accept**.
5. On the **General** tab, enter text that will appear in the Patient Reminder (to be set by the HCP or office staff as appropriate).
    a. Potential example language: *"You have an upcoming appointment for your BLENREP infusion. Before you can start BLENREP, you must receive the BLENREP REMS Patient Guide from your prescriber, receive counseling from your prescriber on the risk of eye problems and the need for eye exams using the Patient Guide. You must enroll in the REMS by completing the Patient Enrollment Form with your prescriber to document that you were counseled on the REMS requirements and agree to get eye exams before starting BLENREP, before each dose, promptly for any new or worsening eye symptoms, and as clinically indicated, as described in the BLENREP REMS Patient Guide. Remember to ask your oncology healthcare team if there are other tests you might need prior to your BLENREP infusion or if you have any questions related to your infusion."*



Illustrative example of SmartText setup (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ophthalmic exams (including slit lamp exam and BCVA assessment) should be conducted by an eye care professional, such as an ophthalmologist or optometrist, at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated. Perform baseline exam within 4 weeks prior to the first dose. Perform each follow-up exam within 10 days prior to the next planned dose. All effort should be made to schedule the exam as close to BLENREP dosing as possible. Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less and resume at same or reduced dose or permanently discontinue based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding the BLENREP Order Group to a Treatment Plan Using the Protocol Builder (cont.)

STEP 2: CREATING A NEW RULE

1. Select **Rule Editor**.
2. Create **New Rule**.
3. Set **Context**: Patient.
4. Add the following in the **Information** section:
   a. **Name**: "BLENREP Treatment MyChart® Reminder"
   b. **Description:** "*Patient future encounter in Medical Oncology department for BLENREP treatment*"
5. Add the following in the **Return Message** section:
   a. Add an appropriate message to be returned by the rule when it passes evaluation, such as "*Patient future encounter in Medical Oncology Department for BLENREP treatment*"
6. Add the following in the **Criteria** section:
   a. **Property 1**: ApptGroup > Appointment Department
      i. **Operator:** Equals
      ii. **Value:** Enter applicable departments, such as Medical Oncology
   b. **Parameter 2**: Appointment Visit Type
      i. **Operator:** Equals
      ii. **Value:** Enter appropriate visit type, such as BLENREP treatment
7. Make note of the Rule ID for later use.

NOTE: *This rule assumes that a unique Visit Type is used for BLENREP treatment appointments.*



Illustrative example of Rule Setup (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Counsel patients to use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional.

Changes in visual acuity may be associated with difficulty for driving and reading. Counsel patients to use caution when driving or operating machinery.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Adding the BLENREP Order Group to a Treatment Plan Using the Protocol Builder (cont.)

STEP 3: CREATING A NEW EXTENSION

1. In **Chronicles**, open **LPP (Extension)**.
2. Enter **Data** > **Duplicate Extension**.
   a. Create a copy of 40422
   b. Name as appropriate, make note of new ID
3. **Enter Data** > **Edit Extension**.
   a. Enter **ID** from new extension created above
4. Edit **Parameters** of extension.
   a. **Body SmartText**: Enter ID of Letter Template created above
   b. **Subject Text**: Optional but recommended for clarity, such as *"Upcoming BLENREP Treatment Reminder"*
   c. **Condition**: Enter ID of the rule created above

STEP 4: CREATING BATCH JOB

1. In **Clinical Administration**, select **Management Options** > **Utilities** > **Batch Menu** > **Job Enter/Edit**.
2. Create a new **Batch Job**. Name the batch job as appropriate, such as MyChart® BLENREP Patient Reminder Job.
   a. **Use Template**: Cadence Generic Appt Looper [80]
   b. **Description**: *"BLENREP Patient Reminder"*
3. Access the **Single and Multiple Response Values** screen and configure the **Mnemonics** as follows:
   a. **!Start Date**: t
   b. **!End Date**: t+7
   c. **!Departments**: ALL (restrictions to specific departments can be entered here)
   d. **Updates Only?:** Yes
4. Enter the extension created in previous step in the **Main LPP** mnemonic.
5. Add **Job** to existing organizational batch for appointment reminders.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

BLENREP Risk Evaluation and Mitigation Strategy (REMS)

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Silent OurPractice Advisory (OPA)

Epic® allows HCPs to draft and set up silent notifications called OPAs that can be sent directly to an In Basket for the care team pool. These notifications do not appear within the patient encounter screens at the point of care. Among other uses, such messages could include a reminder to verify prescriber REMS certification and patient REMS enrollment, complete a BLENREP REMS Eye Care Professional Exam Form, submit a Patient Status Form before each dose of BLENREP, obtain authorization to dispense, or to follow up with patients prior to upcoming infusions to ensure that they have completed their required ophthalmic exams and CBC tests. Additionally, an OPA may be used to remind HCPs about ordering labs or checking REMS requirements such as prescriber certification, patient enrollment, dispensing healthcare setting certification, completed and submitted Patient Status Form, authorization code prior to dispensing, etc.

Steps for Creating an OPA Rule

1. Go to **Chart Search** > **Rule Editor**.
2. Create a **New Rule**.
   a. **Context:** Unsigned Order
   b. **Name:** As applicable per organization standards
3. Click **Accept**.
4. Add property: **Medications [42901]**.
   a. **Operator:** Equal
   b. **Value:** All applicable BLENREP medication records
5. Click **Accept**.
6. Click **Save** (make note of new Rule ID).

Steps for Creating an OPA Criteria Record

1. Go to **Chart Search** > **OurPractice Advisories**.
2. Click the **Create** tab.
3. Select **Record-Type** of **Criteria**.
4. Click **Accept**.
5. In the **Add Criteria Type** window, check **Rule**, then select **+Add**.
6. In the **Rule** section, add the **Rule** created in the previous step.
7. At the top of the form, check **Release**. Then select **Save**.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Thrombocytopenia

Thrombocytopenia of any grade occurred in 100% of patients in DREAMM-7.

Grade 2 thrombocytopenia occurred in 10% of patients, Grade 3 in 29% of patients, and Grade 4 in 45% of patients. Clinically significant bleeding (Grade ≥2) occurred in 7% of patients with concomitant low platelet levels (Grade 3 or 4).

Monitor complete blood cell counts at baseline and periodically during treatment as clinically indicated. Withhold or reduce the dose of BLENREP based on severity.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Silent OurPractice Advisory (OPA) (cont.)

Steps for Creating a Silent OPA Base Record

1. Click **Chart Search** > **OurPractice Advisories**.
2. From the **Create** tab, enter a name; select a **Record-Type** of **Base**.
3. In the **Display** section, enter display text, such as *"New BLENREP Rx"*. This is a silent OPA; descriptive display text will help provide context.
4. Display to user? **No**.
5. Select Importance level: **Informational**.
6. On the **Linked Criteria** form, add the previously built OPA **Criteria** records in the Linked Criteria field and set the logic as appropriate.
7. **Restrictions:** This OPA will be hidden from the end user, but restrictions can be used to restrict where the OPA will be triggered.
8. **Triggers:** Set trigger(s) to determine what activity causes the OPA to display, such as **Sign Order**.
9. From the **Actions** section, select **+Add Action Type**.
10. Select appropriate action type from the **In Basket Message**.
    a. **Subject (set by user):** *"BLENREP Prescription Follow-Up"*
    b. **Message Type (set by user):** *"Confirm REMS requirements"*
    c. **Recipients:** Enter the appropriate user, class, or pool to receive In Basket message notifications to manage patient outreach
    d. **Appearance (example text set by user):** "*This patient has received a BLENREP prescription. Prescribers must be certified in the BLENREP REMS by enrolling and completing training. Prescribers must counsel patients receiving BLENREP on the risk of ocular toxicity, the need for monitoring via ophthalmic exams before each dose, and provide patients with the BLENREP REMS Patient Guide. Patients must be enrolled in the BLENREP REMS and adhere to monitoring. Healthcare settings that dispense BLENREP must be certified in the BLENREP REMS by enrolling and must obtain authorization prior to dispensing. Wholesalers and distributors must distribute BLENREP only to certified healthcare settings. Please see BLENREP USPI for further information.*"
    e. **Frequency:** Always Automatically

NOTE: *Each organization will vary on which pool will receive the messages for patient outreach and the protocol for patient outreach workflow and timing. Individual organizations will determine how to implement timing and pools, as well as developing any associated protocol and message content.*

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Embryo-fetal Toxicity

Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively dividing cells.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Building a Doc Flowsheet to Capture Ocular Adverse Reaction Severity Grade

Doc Flowsheets are templates used for documentation and can be customized to capture the patient's ophthalmic exam results (conducted by either optometrists or ophthalmologists) before administration of BLENREP. Storing exam results within a Doc Flowsheet can provide clinicians with an aggregated view of a patient's eye health and any vision changes over time.

NOTE: *Health systems with on-site eye care may conduct in-house exams, allowing for seamless integration of ophthalmic exam results into the patient's chart. If an ophthalmologist or optometrist is outside of the end user's health system or network, results may need to be manually entered.*

Steps for Building a Doc Flowsheet

1. In **Hyperdrive™**, select **Chart Search** > **Doc Flowsheet Builder**.
2. In the **Create Group/Row** field, type the ID or Name of the new **Flowsheet Row**.
   a. **Name (set by user):** *"Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings"*
   b. **Row Type:** Data
   c. **Value Type:** Custom List
   d. In the **Custom List** section, add applicable options in line with the USPI, such as Grade 1-4 and their respective guidance on recommended dose modifications

Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings[1]	
Grade 1	Continue treatment at current dosage.
Grade 2	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 3	Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. Resume treatment at Reduced Dosage Level 1 as per Table 1. If recurrent Grade 2 or 3 ocular toxicity is experienced, resume treatment at Reduced Dosage Level 2.
Grade 4	Consider permanent discontinuation of BLENREP. If continuing treatment, withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less. For patients previously on 2.5 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 1 as per Table 1. For patients previously on 1.9 mg/kg every 3 weeks, resume treatment at Reduced Dosage Level 2. If recurrent Grade 4 ocular toxicity is experienced, permanently discontinue BLENREP.

For more information on grading definitions and dose modifications for ocular toxicity and non-ocular adverse reactions, please see the full Prescribing Information.

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Embryo-fetal Toxicity (cont.)

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with BLENREP and for 4 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Building a Doc Flowsheet to Capture Ocular Adverse Reaction Severity Grade (cont.)

Steps for Building a Doc Flowsheet (cont.)

3. In the **Create Group/Row** field, type the ID or Name of the new **Flowsheet Row**.
   a. **Display Name:** *"Ophthalmic Exam Overall Grade"*
   b. **Row Type:** Flowsheet Group
   c. In the **Group** section, add applicable rows to the group that was previously created
   d. In **Display** > **Row Information**, enter the information shown in the following table ensuring alignment to the BLENREP USPI

4. In the **Create Template** field, type the ID or Name of the new **Flowsheet**.
   a. **Display Name:** *"Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings"*



Illustrative example of Flowsheet Rows for BLENREP Overall Score (recreated from Epic)

5. In the **Rows and Groups** section, add group previously created.
6. Click **Accept**.



Example of Flowsheet Rows and Groups (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

ADVERSE REACTIONS

The most common adverse reactions (≥20%) with BLENREP in combination with bortezomib and dexamethasone are reduction in BCVA, corneal exam findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, upper respiratory tract infection, hepatotoxicity, eye pain, diarrhea, fatigue, pneumonia, cataract and COVID-19.

The most common Grade 3 or 4 (≥10%) laboratory abnormalities are decreased platelets, decreased lymphocytes, decreased neutrophils, increased gamma-glutamyl transferase, decreased white blood cells, and decreased hemoglobin.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Building a Doc Flowsheet to Capture Ocular Adverse Reaction Severity Grade (cont.)

Steps for Building a Doc Flowsheet (cont.)



Illustrative example of completed Flowsheet setup (recreated from Epic)

INDICATION

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent.

IMPORTANT SAFETY INFORMATION

WARNING: OCULAR TOXICITY

- **BLENREP causes changes in the corneal epithelium resulting in changes in vision, including severe visual impairment, and symptoms such as blurred vision and dry eyes. In the clinical study, corneal ulcers, including cases with infection, also occurred.**
- **Conduct ophthalmic exams at baseline, before each dose, promptly for new or worsening symptoms, and as clinically indicated. In the clinical study, 83% of patients required a dosage modification due to ocular toxicity. Withhold BLENREP until improvement and resume or permanently discontinue, based on severity.**
- **Because of the risk of ocular toxicity, BLENREP is available only through a restricted program called the BLENREP Risk Evaluation and Mitigation Strategy (REMS).**

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade

Review Flowsheets are read-only documents designed for viewing and analyzing data over time. They provide a consolidated view of patient information from multiple visits and may help HCPs monitor changes in the patient's ophthalmic examination findings as provided by their optometrist or ophthalmologist.

Steps for Creating an Ophthalmic Exam Flowsheet

1. Go to **Chart Search** > **Timeline View Editor** and create a timeline record.
   a. **Name (set by user)**: *"Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings"*
   b. Click **Accept**
2. In the **Record Settings** section, enter a **View Type** of Review Flowsheet.
   a. Click **Save**
3. In the **View Settings** section, complete the following fields:
   a. **Display Name**: Clinician-friendly name
   b. **Date Order**: Enter whether the flowsheet initially loads in Chronological or Reverse Chronological order
   c. **Orientation**: Enter whether dates appear as Column Dates or Column Rows
4. Additional information, such as **Initial Load Days** in **Parameters**, can be edited as needed.



Illustrative example of Timeline View Editor (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS

Ocular Toxicity

BLENREP causes ocular toxicity, defined as changes in the corneal epithelium and changes in BCVA based on ophthalmic exam (including slit lamp exam), or other ocular adverse reactions as defined by the CTCAE.

In DREAMM-7, ocular toxicity occurred in 92% of patients, including Grade 3 or 4 in 77% of patients. The most common ocular toxicities (>25%) were reduction in BCVA (89%) and corneal exam findings (86%) based on ophthalmic exam findings, blurred vision (66%), dry eye (51%), photophobia (47%), foreign body sensation in eyes (44%), eye irritation (43%), and eye pain (33%).

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a Flowsheet to Document Ocular Adverse Reaction Severity Grade (cont.)

Steps for Creating an Ophthalmic Exam Flowsheet (cont.)

5. Click the section that was automatically created to edit it:
   a. **Record Name**: *"Recommended Dosage Modifications for Ocular Toxicity based on Ophthalmic Exam Findings"*
   b. **Source**: TIMELINE DOC FLOWSHEET [4160]
   c. **What**: Begin to add Doc Flowsheet rows/groups created for ophthalmic exam flowsheets



Illustrative example of new record Section Editor (recreated from Epic)

6. **Repeat** as needed to add all applicable rows/groups.

7. Once build is complete, save the timeline and make note of the record ID.

Using the Review Flowsheet activity, clinicians can view a trending Overall Grade of patient ophthalmic exam results as they are available over time.



Illustrative example of completed Flowsheet setup (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

Ocular toxicity based on ophthalmic exam findings was reported as Grade 2 in 9% of patients, Grade 3 in 56% of patients, and Grade 4 in 21% of patients. The median time to onset of the first Grade 2 to 4 ophthalmic exam findings was 43 days (range: 15 to 611 days). The median duration of all Grade 2 to 4 ophthalmic exam findings was 85 days (range: 5 to 813 days). Patients experienced a median of 3 episodes (range: 1 to 11 episodes) of ocular toxicity based on ophthalmic exam findings. Of the patients with Grade 2 to 4 ophthalmic exam findings, 42% had improvement of the last event to Grade 1 or better; 22% had resolution of the last event based on return to baseline or normal ophthalmic exam findings.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

Creating a SmartPhrase to View or Document Ocular Adverse Reaction Severity Grade

A SmartPhrase containing a SmartLink can be created to insert documented grading based on ophthalmic exam results into visit notes. SmartPhrases are shortcuts that insert predefined text into patient notes, discharge instructions, or other documentation using an abbreviated phrase. By typing a period (.) followed by the phrase, the predefined text associated with that phrase is automatically inserted. A SmartLink is a tool that can pull in data that is stored in discrete fields within the patient's chart, such as test results or other clinical criteria.

Steps for Creating a SmartPhrase With a SmartLink

1. Go to **Chart Search** > **SmartPhrase** > **Create New System Record**.
2. Name per organization's naming convention.
3. Click **Accept**.
4. In Text field, enter:
   a. .flow[rowID for each group
   b. Click **Enter**
5. Check the box for **Facility** level. It can be further restricted to department profile as appropriate.



Illustrative example of SmartPhrase configuration (recreated from Epic)



Illustrative example of Using SmartPhrase in My Note (recreated from Epic)

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

The most commonly reported corneal exam findings included superficial punctate keratopathy, microcyst-like deposits, epithelial changes, and haze. Cases of corneal ulcer, including cases with infection, have been reported and should be managed promptly by an eye care professional.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

BLENREP
belantamab mafodotin-blmf
for injection 70 mg

IMPORTANT SAFETY INFORMATION (cont.)

WARNINGS AND PRECAUTIONS (cont.)

Ocular Toxicity (cont.)

A reduction in BCVA to 20/50 or worse in at least one eye occurred in 69% of patients, including 29% who experienced a change in BCVA to 20/100 or worse, and 12% who experienced a change in BCVA to 20/200 or worse. Of the patients with reduced BCVA to 20/50 or worse in at least one eye, 61% had resolution of the last event to baseline or better. Of the patients with reduced BCVA to 20/100 or worse, 57% had resolution of the last event. Of the patients with reduced BCVA to 20/200 or worse, 48% had resolution of the last event.

Ophthalmic exams (including slit lamp exam and BCVA assessment) should be conducted by an eye care professional, such as an ophthalmologist or optometrist, at baseline, before each dose of BLENREP, promptly for new or worsening symptoms, and as clinically indicated. Perform baseline exam within 4 weeks prior to the first dose. Perform each follow-up exam within 10 days prior to the next planned dose. All effort should be made to schedule the exam as close to BLENREP dosing as possible. Withhold BLENREP until improvement in both corneal exam findings and change in BCVA to Grade 1 or less and resume at same or reduced dose or permanently discontinue based on severity.

Counsel patients to promptly inform their healthcare provider of any ocular symptoms. Counsel patients to use preservative-free artificial tears at least 4 times a day starting with the first infusion and continuing until the end of treatment, and to avoid wearing contact lenses for the duration of therapy. Bandage contact lenses may be used under the direction of an eye care professional.

Changes in visual acuity may be associated with difficulty for driving and reading. Counsel patients to use caution when driving or operating machinery.

BLENREP Risk Evaluation and Mitigation Strategy (REMS)

BLENREP is available only through a restricted program called the BLENREP REMS because of the risk of ocular toxicity.

Further information is available at www.BLENREPREMS.com and 1-855-690-9572.

Thrombocytopenia

Thrombocytopenia of any grade occurred in 100% of patients in DREAMM-7.

Grade 2 thrombocytopenia occurred in 10% of patients, Grade 3 in 29% of patients, and Grade 4 in 45% of patients. Clinically significant bleeding (Grade ≥2) occurred in 7% of patients with concomitant low platelet levels (Grade 3 or 4).

Monitor complete blood cell counts at baseline and periodically during treatment as clinically indicated. Withhold or reduce the dose of BLENREP based on severity.

Embryo-fetal Toxicity

Based on its mechanism of action, BLENREP can cause fetal harm when administered to a pregnant woman because it contains a genotoxic compound (the microtubule inhibitor, monomethyl auristatin F [MMAF]) and it targets actively dividing cells.

Reference: 1. BLENREP. Prescribing Information. GSK; 2025.

Please see additional Important Safety Information throughout and click here for full Prescribing Information including Boxed Warning for BLENREP.

PMUS-BLMBRGD250001 October 2025
Produced in USA.

BLENREP belantamab mafodotin-blmf for injection 70 mg